에 대한 최신 뉴스 Legend Biotech (NASDAQ:LEGN) 주식

Legend Biotech

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Large Cap

News

Movers

General

COIN

EPAM

INFY

LEGN

MSTR

TOST

VTRS

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?

워너 브라더스와 코인베이스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (7월 14일-7월 20일)

Legend Biotech Corporation - American Depositary Shares

Legend Biotech Corp

The CNN Money Fear and Greed index showed some easing in the fear level, with the index moving to the &#8220;Fear&#8221; zone on Friday.
U.S. stocks settled higher on Friday, with the Dow Jones index surging almost 500 points during the session.
Even as the major indices recorded gains on Friday, all three averages fell last week. The Dow dipped around 2.3% to record its third losing week in a row. The S&amp;P 500 declined about 2%, while the Nasdaq Composite fell around 1.8% last week.
On the economic data front, the U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%. The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, versus a reading of 71.8 in November.
Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) reported better-than-expected earnings for its fourth quarter on Friday.
All sectors on the S&amp;P 500 closed on a positive note, with utilities, real estate, and information technology stocks recording the biggest gains on Friday.
The Dow Jones closed higher by around 498 points to 42,840.26 on Friday. The S&amp;P 500 rose 1.09% to 5,930.85, while the Nasdaq Composite surged 1.03% to close at 19,572.60 during Friday's session.
Investors are awaiting earnings results from Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>), Bridgeline Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>), and Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 28.1, the index moved to the &#8220;Fear&#8221; zone on Friday, versus a prior reading of 21.9.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Markets

AVXL

BLIN

LMNR

Dow Jumps Around 500 Points But Records 3rd Straight Weekly Loss: Greed Index Moves To 'Fear' Zone

Steve Ballmer, the former Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)&nbsp; CEO has placed more than 80% of his investment portfolio in one stock, and his approach has paid off handsomely.
What Happened: In a Q&amp;A <a href="https://www.wsj.com/finance/investing/steve-ballmer-the-non-investing-guru-of-investing-b0058c11">with</a> The Wall Street Journal that was published on Sunday, Ballmer shared that over 80% of his holdings are tied to his former company, Microsoft, with the remainder invested in stock index funds.
He attributes his financial success to Microsoft&#8217;s strong performance, particularly after the AI boom sparked by Microsoft-backed OpenAI&#8217;s ChatGPT in November 2022.
"Microsoft's outperformed just about every other asset I could have owned," he stated, adding, "It's a little hard to say that it hasn't worked out."
See Also: <a href="https://www.benzinga.com/tech/24/12/42608964/samsung-one-ui-6-1-1-update-is-turning-this-galaxy-series-phones-into-paperweights-bricking-random-reboots-and-overheating-reported?itm_source=parsely-api">Samsung One UI 6.1.1 Update Is Turning This Galaxy Series Phones Into Paperweights: Bricking, Random Reboots And Overheating Reported</a>
Ballmer <a href="https://www.benzinga.com/markets/24/12/42638406/tech-titans-triumph-the-top-10-billionaires-who-made-big-gains-in-2024">holds a 4.5% stake in Microsoft</a>. Since 2020 till now, Microsoft has returned an average of 28.37% annually, significantly outperforming the S&amp;P 500's average return of around 11.08%.
When Ballmer was asked if his strategy applies to everyday investors, he said, &#8220;I'd suggest keeping it simple—unless you're truly committed to becoming an expert.&#8221;
Microsoft currently has a market capitalization of $3.346 trillion, making it the third most valuable company in the world. According to <a href="https://benzinga.grsm.io/lxquj26b2sag">data from Benzinga Pro</a>, Microsoft shares have risen by 17.72% year-to-date.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Ballmer&#8217;s strategy is influenced by Warren Buffett, who recommends S&amp;P 500 index funds <a href="https://www.benzinga.com/startups/24/10/41252767/warren-buffetts-timeless-advice-is-to-invest-in-stocks-that-youd-be-perfectly-happy-to-hold-if-the-m">for retail investors</a>.
Now worth $151 billion, according to the Bloomberg Billionaire <a href="https://www.bloomberg.com/billionaires/">Index</a>, Ballmer also has a significant investment in the Los Angeles Clippers, which has appreciated since his $2 billion purchase in 2014, now <a href="https://www.forbes.com/teams/los-angeles-clippers/">valued</a> at $5.5 billion.
Earlier this year, <a href="https://www.benzinga.com/markets/equities/24/07/39588200/bill-gates-hired-steve-ballmer-as-the-first-business-manager-at-microsoft-and-now-is-behind-him-">Ballmer&#8217;s wealth surpassed</a> that of Microsoft co-founder Bill Gates. Although, at the time of writing, Gates is at number seven on the Index with a net worth of $160 billion.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42609242/marques-brownlee-breaks-down-how-googles-ai-video-generator-veo2-outpaces-openais-sora?itm_source=parsely-api">Marques Brownlee Breaks Down How Google&#8217;s AI Video Generator Veo2 Outpaces OpenAI&#8217;s Sora</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Tech

Media

MSFT

Steve Ballmer's Bold Investment Strategy: 80% Of His Portfolio Is In Microsoft Stock – Here's Why His 'Keep It Simple' Approach Is Winning Big

Goldman Sachs analyst Allen Chang initiates coverage on Pony AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) with a Buy rating and announces Price Target of $19.6.

Price Target

Initiation

Analyst Ratings

PONY

Goldman Sachs Initiates Coverage On Pony AI with Buy Rating, Announces Price Target of $19.6

&nbsp;Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its stock will be added to the Nasdaq Biotechnology Index (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBI#NASDAQ">NBI</a>). The addition comes as a part of the annual reconstitution of the index. Alvotech's inclusion in the NBI will be effective when the U.S. market opens on Monday, December 23, 2024.

Government

Regulations

ALVO

Alvotech Joins Nasdaq Biotech Index, Effective Today

As the largest publicly traded dedicated non-operator, NOG has a large pipeline of acquisition opportunities and the Company frequently sends expressions of interest to acquire assets or businesses in order to evaluate and conduct due diligence on potential opportunities. Many of these requests to conduct diligence are rejected. The Company is not currently engaged in formal negotiations to acquire Granite Ridge.

Reported Friday, NOG Addressed Speculation On Granite Ridge Acquisition, Confirms No Formal Negotiations

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) to report a quarterly loss at 7 cents per share on revenue of <a href="https://www.benzinga.com/quote/LMNR/earnings">$42.45 million after</a> the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Limoneira shares gained 2% to $26.83 in after-hours trading.</li>
<li>Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) bagged a key win in its legal battle against semiconductor design company Arm Holdings Plc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>). A federal jury in Delaware ruled that Qualcomm did not violate its licensing agreement with Arm, clearing a hurdle for the San Diego, California-<a href="https://www.benzinga.com/24/12/42633922/qualcomm-bags-win-in-chips-licensing-trial-against-arm-but-the-battle-is-not-over-yet">headquartered chipmaker</a>. Qualcomm shares gained 1.9% to $155.72 in the after-hours trading session.</li>
<li>Analysts expect Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) to post a quarterly loss at 16 cents per share before the opening bell. Anavex Life Sciences shares gained 0.2% to $8.65 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Brenmiller Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) shares rose sharply in after-hours trading on Friday after the company said it was awarded ISO/IEC 27001:2022 certification. Brenmiller Energy shares surged 12% to $0.8440 in the after-hours trading session.</li>
<li>Analysts expect Bridgeline Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) to post a quarterly loss at 5 cents per share on revenue of $3.87 million after the closing bell. Bridgeline Digital shares fell 0.7% to $1.48 in after-hours trading.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Trading Ideas

BNRG

QCOM

Qualcomm, Limoneira And 3 Stocks To Watch Heading Into Monday

SGML

Reported Friday, Sigma Lithium Secures Unanimous Approval For Triple Environmental License At Barreiro Mine

Fund manager Stephen Yiu of Blue Whale Growth Fund has forecasted that&nbsp;Broadcom Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) will yield substantial returns for investors by 2025, potentially surpassing AI chip heavyweight&nbsp;Nvidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
What Happened: Yiu said that tech giants like Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Google LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) are looking to broaden their AI chip supplier base. Despite their substantial purchases of Nvidia&#8217;s GPUs, these companies are now also creating their own custom chips for AI applications, CNBC<a href="https://www.cnbc.com/2024/12/23/-the-next-nvidia-broadcom-is-the-ai-chip-stock-to-own-in-2025-investor-says.html"> reported</a> on Monday.
Yiu sees Broadcom as&nbsp;the next Nvidia in terms&nbsp;of potential outperformance, thanks to its strong partnerships with major tech firms. 
&#8220;Nvidia's&nbsp;GPUs are very powerful, but&nbsp;at the same time also&nbsp;very expensive,&#8221; Yiu noted. &#8220;From&nbsp;Microsoft's perspective, you don't want&nbsp;to become overly dependent on&nbsp;one single supplier.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/12/42624559/warren-buffett-says-a-surge-in-people-doing-big-dumb-things-is-tied-to-historically-easy-access-to-other-peoples-money?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Warren Buffett Says A Surge In People Doing &#8216;Big Dumb Things&#8217; Is Tied To Historically Easy Access To Other People&#8217;s Money</a>
Broadcom&#8217;s year to date returns have climbed 103.42% this year, as of Monday pre-market hours, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>. It hit a market cap of over $1 trillion after announcing that its AI revenue&nbsp;tripled to $12.2 billion in&nbsp;2024. The company is working&nbsp;with three major cloud computing&nbsp;customers, Meta, Alphabet, and ByteDance, to develop custom AI chips.
Despite still holding an investment in Nvidia, Yiu has significantly cut it from nearly 10% of his fund's portfolio. He views Broadcom as a more attractive investment opportunity due to its smaller size. 
&#8220;For&nbsp;a $1 trillion company to&nbsp;grow 50% to become $1.5&nbsp;trillion is reasonable. But for&nbsp;Nvidia to do that, they&nbsp;would need to add another&nbsp;$1.5 trillion, which is a&nbsp;very big number,&#8221; he elaborated.
Why It Matters: Broadcom&#8217;s CEO Hock Tan has <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42613368/broadcom-expects-decade-long-ai-chip-boom-as-big-tech-invest-billions">expressed strong confidence</a> in the sustainability of the AI boom. Big tech companies like Google, Meta, and ByteDance are investing heavily in designing custom processors to accelerate the training and deployment of AI systems. Even OpenAI and Apple have partnered with Broadcom to develop their AI server chips, diversifying their exposure to Nvidia.
Kurv Investment Management&#8217;s CEO Howard Chan recently mentioned that chipmakers like <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42600155/exclusive-nvidia-broadcom-tipped-to-dominate-ai-compute-wave-by-kurv-ceo">Nvidia and Broadcom </a>are leading the AI wave. He noted that demand is outstripping supply in this sector, benefiting chipmakers and cloud computing service providers.
Former House Speaker Nancy Pelosi (D-Calif.), known for her active stock market investments as a member of Congress, disclosed in June that she had <a href="https://www.benzinga.com/news/24/09/40692177/whats-going-on-with-broadcom-shares-today" target="_blank" rel="noreferrer noopener">acquired call options on Broadcom. </a>These options, adjusted to a strike price of $80 after a 10-for-1 stock split, are set to expire in June 2025.
Pelosi, a widely followed Congressional trader, has drawn <a href="https://www.benzinga.com/news/24/09/40692177/whats-going-on-with-broadcom-shares-today">significant attention to her stock holdings,</a> inspiring dedicated Pelosi portfolio trackers. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42628397/bitcoin-ethereum-xrp-dogecoin-recover-from-days-losses-if-this-is-the-christmas-sell-off-and-the-top-so-be-it-trader-says?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Recover From Day&#8217;s Losses: &#8216;If This Is The Christmas Sell Off And The Top, So Be It,&#8217; Trader Says</a></li>
</ul>
Image via Shutterstock

AMZN

AVGO

GOOGL

NVDA

Is This Nancy Pelosi's Stock Pick Set To Overtake Nvidia? AI Chip Race To Heat Up By 2025 As Meta And Microsoft Look Beyond Jensen Huang's Chip Maker, Says Expert

<h3>Companies Reporting Before The Bell</h3>
• Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) is expected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Bridgeline Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $3.87 million. 
• Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) is expected to report quarterly loss at $0.07 per share on revenue of $42.45 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Scheduled For December 23, 2024

WHLM

Reported Friday, Wilhelmina International Confirms Nasdaq Delisting, Last Trading Day Expected December 31, 2024

GLDG

Reported Friday, GoldMining Renews At-The-Market Program For Up To $50M In Common Shares

Macro Economic Events

Econ #s

Economics

U.K. Gross Domestic Product (YoY) For Q3 0.9% Vs. 1.0% Est.; 0.7% Prior

U.K. Gross Domestic Product (QoQ) For Q3 0.0% Vs. 0.1% Est.; 0.4% (Revised) Prior

U.K. Current Account For Q3 -18.1B Vs. -22.9B Est.; 24.0B (Revised) Prior

U.K. Business Investment (QoQ) For Q3 1.9% Vs. 1.2% Est.; 1.8% (Revised) Prior

The<a href="https://www.benzinga.com/money/how-to-invest-in-the-sp-500"> S&amp;P 500 </a>is flashing a rare technical warning signal that hasn&#8217;t been seen since the Jimmy Carter administration, with declining stocks dominating market action for 14 consecutive days through Thursday.
What Happened: &#8220;Market tops have to start somewhere, and many begin with breadth divergences,&#8221; warns Ed Clissold, chief U.S. strategist at NDR, noting this marks the longest decline streak since Oct. 15, 1978, Business Insider <a href="https://markets.businessinsider.com/news/stocks/stock-market-outlook-risk-signal-breadth-sp500-investor-sentiment-returns-2024-12">reported</a> on Monday. 
The troubling market breadth comes as the benchmark index trades just 4% below its record high, masking deeper problems beneath the surface. The equal-weighted S&amp;P 500, which better reflects the typical stock&#8217;s performance, has already fallen 7% from its peak.
Historical data paints a concerning picture for investors. After similar breadth declines since 1972, the S&amp;P 500 has averaged just 0.1% returns over the following six months – significantly below the typical 4.5% gain seen during all periods.
The market faces a critical test heading into the traditionally bullish year-end period. &#8220;A lack of a <a href="https://www.benzinga.com/24/12/42627985/which-magnificent-7-stock-will-gain-the-most-in-a-santa-claus-rally-28-select">Santa Claus Rally</a> would be concerning not only from a seasonal perspective, but it would allow breadth divergences to deepen,&#8221; Clissold cautioned.
Adding to the worries, NDR&#8217;s sentiment indicators show investors have maintained extreme optimism since September, marking the seventh-longest stretch of excessive bullishness since 1995. This optimism, combined with the Federal Reserve&#8217;s recent hawkish stance on 2025 interest rate cuts, has pushed the market toward its worst weekly performance since March 2023.
&#8220;If the stock market cannot rectify recent breadth divergences in the next few weeks, it would suggest our concerns about a more difficult 2025 could come to fruition,&#8221; Clissold concluded.
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42639832/bitcoin-ethereum-dogecoin-lose-sheen-ahead-of-holidays-but-top-analyst-points-to-this-indicator-says-btc-will-hit-a-top-above-168k">Bitcoin, Ethereum, Dogecoin Lose Sheen Ahead Of Holidays But Top Analyst Points To This Indicator, Says BTC Will Hit A Top Above $168K</a>
Why It Matters: The term &#8220;Santa Claus rally&#8221; was coined by Yale Hirsch in 1972 in the &#8220;Stock Trader&#8217;s Almanac.&#8221; It refers to the tendency for <a href="https://www.benzinga.com/general/education/24/12/42625025/santa-claus-rally-in-2024-poll-shows-investors-split-on-end-of-year-returns-57-say-this">stock prices to rise </a>during the final five trading days of the year and the first two trading days of the following year. This period often sees higher prices due to factors such as year-end portfolio rebalancing, positive holiday sales reports, and optimism for the year ahead, all of which can contribute to strong returns for major stock market indexes.
When Benzinga asked if readers expect a Santa Clause rally, 57% responded that they expect one.
The S&amp;P 500 warning comes even as the <a href="https://www.benzinga.com/24/12/42627688/dow-surges-over-600-points-gold-jumps-1-5">index surged over</a> 1.5% to 5,956.61 on Friday.
The conflicting signals come as the benchmark index approaches what could be its <a href="https://www.benzinga.com/24/12/42430296/carson-researchs-50-year-study-suggests-that-the-26-months-old-bull-market-is-far-from-over">best election year</a> performance ever, having already notched 56 new all-time highs in 2024, according to Carson Research&#8217;s chief market strategist Ryan Detrick.
Price Action: Meanwhile, on Friday, the Dow traded up 1.55% to 43,000.53 while the NASDAQ rose 1.65% to 19,693.06. The S&amp;P 500 also rose, gaining, 1.53% to 5,956.61. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which closely monitors the S&amp;P 500 closed 1.20% higher and Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) closed 0.87% higher, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42639832/bitcoin-ethereum-dogecoin-lose-sheen-ahead-of-holidays-but-top-analyst-points-to-this-indicator-says-btc-will-hit-a-top-above-168k">Crypto Analyst: ‘2025 Will Continue To Be a Great Year for Bitcoin'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Analyst Color

'A Lack Of A Santa Claus Rally Would Be Concerning,' Says Analyst As S&P 500 Breadth Hits Lowest Since Jimmy Carter Era

ICL Appoints Elad Aharonson As President And CEO, Effective March 13, 2025

Rate decision supports investments in battery storage, transmission infrastructure and maintenance to improve reliability for customers.

Reported Friday, PGE Receives Approval For 2025 Rates, Supporting Critical Investments In Battery Storage And Grid Modernization

Reported Saturday, EHang Partners With Changan Automobile To Redefine Personal Transportation Through Innovative Flying Cars

RKLB

Reported Saturday, Rocket Lab Concludes 2024 With 16th Mission, Delivering Synspective Satellite And Celebrating Unprecedented Launch Cadence

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN – Research Report), Disc Medici...

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Xenon (XENE – Research Report), Legend Biotech (LE...

Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Legend Biotech (LEGN) and Gilead Sciences (GILD)

Oppenheimer raised the firm's price target on Gilead (GILD) to $115 from $105 and keeps an Outperform rating on the shares after partner Arcellx (A...

Gilead price target raised to $115 from $105 at Oppenheimer

The company states: "Legend Biotech (LEGN) announced new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI, ciltac...

Legend Biotech's Phase 3 study of CARVYKTI shows 'improved disease negativity'

William Blair analyst Sami Corwin maintained a Hold rating on Legend Biotech (LEGN – Research Report) today. The company's shares closed yesterday ...

William Blair Sticks to Its Hold Rating for Legend Biotech (LEGN)

Legend Biotech (LEGN) has released an update. Legend Biotech's CARVYKTI&#xAE; has demonstrated a significant improvement in minimal residual disease neg...

Legend Biotech's CARVYKTI® Boosts Myeloma Treatment Success

UBS analyst Ashwani Verma raised the firm's price target on Arcellx (ACLX) to $114 from $106 and keeps a Buy rating on the shares. UBS believes Arc...

Arcellx price target raised to $114 from $106 at UBS

Luncheon Meeting with Management to be held in New York on December 16 hosted by Piper Sandler. Published first on TheFly – the ultimate source for...

Legend Biotech management to meet with Piper Sandler

Harbor Health Care ETF Q3 2024 Commentary

25 U.S. 'highest conviction' stocks – UBS

ACLX

ASND

ATZAF

BBIO

CGNX

CYBR

DELL

DXCM

FCNCA

FSLR

GILD

ICLR

IRON

MEDI

MRUS

NBIX

ORCL

SPGI

SRPT

ULTA

XENE

Press Releases

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Health Care

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Genmab

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Vaxcyte

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

HC Wainwright & Co.

Cantor Fitzgerald

RBC Capital

Redburn Atlantic

Scotiabank

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/39838603" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">기존 텔레비전 네트워크</a>에서 디지털 스트리밍 및 스튜디오 사업을 분할하려는 계획을 논의했다는 보고 이후 18.28% 상승했다.</li>
<li>마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 지난주 비트코인 가격의 상승 속에서 16.74% 상승했다.</li>
<li>D.R. 호튼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 FY24 지침을 수정한 후 12.91% 급등했다. 회사는 또한 <a href="https://www.benzinga.com//node/39845136" target="_blank" rel="noreferrer noopener">새로운 40억 달러 규모의</a> 자사 주식 매입을 승인했다. 주식에 대한 목표 주가를 <a href="https://www.benzinga.com/quote/dhi/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>을 한 분석가는 거의 없다.</li>
<li>코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 지난주 비트코인 가격 상승의 영향으로 12.39% 상승했다.</li>
<li>블루 아울 캐피털(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OQL#NYSE">OQL</a>)은 블룸버그가 아탈라야(Atalaya)를 약 8억 달러에 매수할 계획이라고 <a href="https://www.bloomberg.com/news/articles/2024-07-16/blue-owl-to-buy-private-credit-firm-atalaya-adding-10-billion-in-assets?sref=2h1zKciy" target="_blank" rel="noreferrer noopener">발표</a>한 후 7.89% 상승했다.</li>
<li>유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)의 주가는 <a href="https://www.benzinga.com//node/39790051" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 실적 호조</a>에 따라 7.84% 상승했다. 많은 분석가들이 주식에 대한 가격 예측을 <a href="https://www.benzinga.com//node/39814804" target="_blank" rel="noreferrer noopener">상향 조정했</a>다.</li>
<li>스테이트 스트리트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>)는 예상보다 나은 <a href="https://www.benzinga.com//node/39795949" target="_blank" rel="noreferrer noopener">2분기</a> 실적에 힘입어 7.21% 급등했다. 몇몇 분석가들은 주식 가격 예측을 <a href="https://www.benzinga.com//node/39822388" target="_blank" rel="noreferrer noopener">수정</a>했다. </li>
<li>레나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>)는 다른 주택 건설업체 주식들과의 공감을 이유로 7.07% 상승했다.</li>
<li>토스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)는 미즈호(Mizuho)가 주식을 중립에서 아웃퍼폼(Outperform)으로 <a href="https://www.benzinga.com/quote/TOST/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">상향 조정하고</a> 목표 주가를 21달러에서 33달러로 상향 조정한 후 지난주 주가는 7.05% 상승했다. </li>
<li>이팸 시스템(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>)의 주식은 제프리스(Jefferies)의 분석가가 <a href="https://www.benzinga.com/quote/epam/analyst-ratings" target="_blank" rel="noreferrer noopener">보유에서 매수로</a> 등급을 올린 후 6.97% 상승했다.</li>
</ol>
사진=Shutterstock의 rafapress






Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Legend Biotech

뉴스

에 대한 최신 뉴스 Legend Biotech (NASDAQ:LEGN) 주식

월요일, 7월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌